BRPI9916820B8 - composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método - Google Patents

composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método

Info

Publication number
BRPI9916820B8
BRPI9916820B8 BRPI9916820A BRPI9916820A BRPI9916820B8 BR PI9916820 B8 BRPI9916820 B8 BR PI9916820B8 BR PI9916820 A BRPI9916820 A BR PI9916820A BR PI9916820 A BRPI9916820 A BR PI9916820A BR PI9916820 B8 BRPI9916820 B8 BR PI9916820B8
Authority
BR
Brazil
Prior art keywords
pivaloyloxy
phosphono
adenine
methoxy
bis
Prior art date
Application number
BRPI9916820A
Other languages
English (en)
Inventor
C Dahl Terrence
J Yuan Lung-Chi
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/211,613 external-priority patent/US6635278B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI9916820A2 publication Critical patent/BRPI9916820A2/pt
Publication of BRPI9916820B1 publication Critical patent/BRPI9916820B1/pt
Publication of BRPI9916820B8 publication Critical patent/BRPI9916820B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "FORMULAÇÕES FARMACÊUTICAS". A invenção fornece composições que compreendem o análogo de nucleotídeo 9-[2-[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina e um excipiente alcalino com ou sem L-carnitina-L-tartarato. As composições são mais estáveis do que aquelas anteriormente descritas. A invenção também fornece métodos para produzir as composições e seus intermediários.
BRPI9916820A 1998-12-15 1999-12-14 composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método BRPI9916820B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11240398P 1998-12-15 1998-12-15
US09/211,613 1998-12-15
US60/112,403 1998-12-15
US09/211,613 US6635278B1 (en) 1998-12-15 1998-12-15 Pharmaceutical formulations
PCT/US1999/029626 WO2000035460A2 (en) 1998-12-15 1999-12-14 Pharmaceutical formulations

Publications (3)

Publication Number Publication Date
BRPI9916820A2 BRPI9916820A2 (pt) 2001-10-30
BRPI9916820B1 BRPI9916820B1 (pt) 2018-04-03
BRPI9916820B8 true BRPI9916820B8 (pt) 2023-04-25

Family

ID=26809911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9916820A BRPI9916820B8 (pt) 1998-12-15 1999-12-14 composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método

Country Status (18)

Country Link
EP (1) EP1140114B1 (pt)
JP (1) JP4750946B2 (pt)
KR (1) KR100624214B1 (pt)
CN (2) CN1202829C (pt)
AR (1) AR021670A1 (pt)
AT (1) ATE298576T1 (pt)
AU (1) AU759869B2 (pt)
BR (1) BRPI9916820B8 (pt)
CA (1) CA2355239C (pt)
CO (1) CO5261557A1 (pt)
DE (1) DE69926012T2 (pt)
ES (1) ES2245130T3 (pt)
ID (1) ID30032A (pt)
MY (1) MY126526A (pt)
NZ (1) NZ511855A (pt)
TR (1) TR200101746T2 (pt)
TW (1) TWI230618B (pt)
WO (1) WO2000035460A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
HRP20031073A2 (en) * 2001-07-31 2004-04-30 Lundbeck & Co As H Crystalline composition containing escitalopram
KR20050086519A (ko) * 2002-11-12 2005-08-30 티안진 킨슬리 파마슈티컬 컴퍼니 리미티드 새로운 결정 형태를 가진 아데포비어 디피복실 및 그조성물
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
KR20100031045A (ko) * 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
CN102149715A (zh) 2008-09-17 2011-08-10 Cj第一制糖株式会社 肝适能的稳定化固态分散物及其制备方法
KR101089620B1 (ko) * 2009-07-20 2011-12-06 경희대학교 산학협력단 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
EP2343056A1 (en) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
HUE060517T2 (hu) * 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
EP4696303A1 (en) * 2024-08-14 2026-02-18 Bonutra AG All natural granulate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201726A (ja) * 1982-05-18 1983-11-24 Meiji Seika Kaisha Ltd 安定な製剤の製造法
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
US4704365A (en) * 1986-02-24 1987-11-03 Abbott Laboratories Composition and method for stabilization of dinucleotides
CA2035841C (en) * 1990-02-22 1996-02-13 Harry B. Demopoulos Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
JPH0825905B2 (ja) * 1990-11-20 1996-03-13 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
JP2974550B2 (ja) * 1993-06-01 1999-11-10 ビオフェルミン製薬株式会社 経口投与用固体組成物
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
JP2762998B2 (ja) * 1997-04-25 1998-06-11 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
JPH114666A (ja) * 1997-06-17 1999-01-12 Otsuka Pharmaceut Co Ltd マグネシウム補給発泡剤組成物
TR200200137T2 (tr) * 1997-07-25 2002-09-23 Gilead Sciences, Inc. Nükleotid analog kompozisyonlar.

Also Published As

Publication number Publication date
MY126526A (en) 2006-10-31
WO2000035460A2 (en) 2000-06-22
CA2355239A1 (en) 2000-06-22
DE69926012D1 (de) 2005-08-04
CO5261557A1 (es) 2003-03-31
EP1140114B1 (en) 2005-06-29
JP2002532429A (ja) 2002-10-02
BRPI9916820A2 (pt) 2001-10-30
AU2361300A (en) 2000-07-03
CA2355239C (en) 2008-03-18
CN1330547A (zh) 2002-01-09
KR100624214B1 (ko) 2006-09-18
TWI230618B (en) 2005-04-11
CN100361664C (zh) 2008-01-16
JP4750946B2 (ja) 2011-08-17
CN1202829C (zh) 2005-05-25
AR021670A1 (es) 2002-07-31
TR200101746T2 (tr) 2001-12-21
KR20010080765A (ko) 2001-08-22
NZ511855A (en) 2003-07-25
HK1040488A1 (en) 2002-06-14
WO2000035460A3 (en) 2000-11-09
DE69926012T2 (de) 2006-05-04
AU759869B2 (en) 2003-05-01
EP1140114A2 (en) 2001-10-10
CN1682743A (zh) 2005-10-19
BRPI9916820B1 (pt) 2018-04-03
ID30032A (id) 2001-11-01
ES2245130T3 (es) 2005-12-16
ATE298576T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
SE9701398D0 (sv) Novel compounds
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
PT1412384E (pt) Formulação estável de glp-1 modificado
PT911333E (pt) Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
ATE250623T1 (de) 4'-c-ethynyl-purin-nukleoside
EE200200208A (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
AU6617596A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, their preparation process, their use as medicaments, and pharmaceutical compositions containing them
BRPI9916820A2 (pt) Formulações farmacêuticas
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
AU7270798A (en) Antithrombotic agents
ATE251162T1 (de) Triazolo(4,5-d)pyrimidin-verbindungen
BR0308601A (pt) inibidores de carboxipeptidase b de plasma
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
AU7470098A (en) Antithrombotic agents
YU87501A (sh) Farmaceutski kompleksi
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
MY118946A (en) Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides
SE9803107D0 (sv) Novel Compunds

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO ( ART. 25 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2465 DE 03/04/2018 QUANTO AO PRAZO DE VALIDADE. (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/1999, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/12/2019